Core Insights - Nano-X Imaging (NASDAQ: NNOX) is a small innovation-focused biotech company that has gained attention in the biotech industry over the past two years [1]. Company Overview - The company operates within the healthcare sector, which has been experiencing significant developments and changes [1]. Investment Perspective - The company has been identified as a potential investment opportunity due to its focus on innovation in the biotech field [1].

Financial Data and Key Metrics Changes - The company reported a GAAP net loss of $13.6 million for Q3 2024, a decrease from a net loss of $21.4 million in Q3 2023, primarily due to a reduction in impairment-related expenses [48] - Revenue for Q3 2024 was $3.0 million, compared to $2.5 million in the same period last year, with a gross loss of $2.8 million on a GAAP basis [49] - Non-GAAP gross loss for the reported period was $0.2 million, compared to a non-GAAP gross profit of $0.9 million in the comparable period, indicating a significant shift in profitability metrics [50] Business Line Data and Key Metrics Changes - Revenue from teleradiology services reached a record $2.6 million in Q3 2024, with a gross profit margin of approximately 15% on a GAAP basis, up from $2.2 million and 11% in Q3 2023 [51][52] - Revenue from AI solutions increased to $0.4 million in Q3 2024 from $0.1 million in the same period last year, attributed to the completion of installation projects [54] - Revenue from imaging systems sales was minimal at $29,000, with a gross loss of $1.5 million, reflecting ongoing challenges in this segment [55] Market Data and Key Metrics Changes - The company has deployed 47 Nanox.ARC units across the U.S., with a focus on small and medium imaging centers, as well as some hospitals and clinics [68] - The company is actively pursuing regulatory approvals in various international markets, including Mexico and Chile, to expand its footprint [21][80] Company Strategy and Development Direction - The strategic growth plan includes doubling the pipeline and expanding sales, service, and support teams in the U.S. to enhance market penetration [8][15] - The company aims to secure CE Mark designation in the EU and is working closely with the FDA for additional clearances, which are expected to significantly expand the total addressable market [24][62] - The focus on innovation and strategic partnerships is expected to drive shareholder value, with recent collaborations with prestigious institutions like Oxford University Hospitals [10][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the transformative potential of Nanox.ARC technology and its ability to make advanced medical imaging accessible and affordable [13][62] - Positive feedback from healthcare providers and ongoing clinical trials are seen as critical to driving broader adoption of the company's solutions [63] - The company is preparing for significant milestones in 2025, including regulatory approvals and product launches, which are anticipated to enhance revenue growth [95] Other Important Information - The company has a cash position of approximately $57.1 million as of September 30, 2024, with a loan of $3.4 million from a bank [59] - The Nanox.AI solution has been recognized in Time's Best Inventions of 2024, highlighting its impact on the healthcare industry [11] Q&A Session Summary Question: How many systems were deployed in the U.S. during the quarter? - The company deployed a total of 47 systems, primarily in small and medium imaging centers, with some in hospitals and clinics [68] Question: How has average utilization trended for ARC? - Average utilization remains around seven scans per day in operating locations [69] Question: Any updates on FDA conversations and ARC-X? - Conversations with the FDA are positive, and the company plans to submit for ARC-X approval early next year [70][71] Question: What are the plans for Europe post-CE Mark? - The company plans to utilize distributors for sales in Europe, with a go-to-market strategy already in place [76][78] Question: What about regulatory efforts in LATAM? - Regulatory approvals in Mexico and Chile are being pursued by distributors, with ongoing communication to facilitate the process [80] Question: When should we expect an inflection point in revenue? - The company anticipates multiple milestones that could serve as inflection points, including regulatory approvals and product launches [94][95]

Exhibit 99.1 Nanox Announces Third Quarter of 2024 Financial Results and Provides Business Update Made progress deploying all components of the Nanox solution including Nanox.ARC and Nanox.AI Expanded US sales and support staf a key component of global strategic growth plan Management to host conference call and webcast Thursday, November 21, 2024 at 8:30 AM ET PETACH TIKVA, Israel — November 21, 2024 — NANO-X IMAGING LTD (NASDAQ: NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology co ...

Core Viewpoint - Nanox Imaging Ltd is set to report its financial results for Q3 2024 on November 21, 2024, with a conference call scheduled for 8:30 a.m. ET to discuss the results and provide a business update [1]. Company Overview - Nanox is focused on transitioning the world to preventive healthcare through affordable medical imaging technologies that utilize advanced AI and novel digital sources [3]. - The company's vision includes expanding the reach of its technology beyond hospital settings, providing a comprehensive solution from scan to diagnosis, and leveraging AI for enhanced diagnostics [4]. Product Ecosystem - Nanox.ARC: A multi-source Digital Tomosynthesis system that is cost-effective and user-friendly [4]. - Nanox.AI: An AI-based suite of algorithms that enhances routine CT imaging readings to identify early signs of chronic diseases [4]. - Nanox.CLOUD: A cloud-based platform for managing and storing data from Nanox devices, offering tools for detailed imaging analysis [4]. - Nanox.MARKETPLACE: A decentralized marketplace providing remote access to radiology and cardiology experts, along with a teleradiology services platform [4]. Business Strategy - By improving early detection and treatment, Nanox aims to enhance health outcomes globally [4].

PETACH TIKVA, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that Company management will participate in an investor conference in the month of September 2024: Cantor Fitzgerald Global Healthcare Conference About Cantor Fitzgerald Global Healthcare Conference Nanox's Chief Executive Officer and Acting Chairman, Erez Meltzer, and Chief Financial Officer, Ran Daniel, will engage in a fire ...

The price trend for Nano-X Imaging Ltd. (NNOX) has been bearish lately and the stock has lost 19.7% over the past four weeks. However, the formation of a hammer chart pattern in its last trading session indicates that the stock could witness a trend reversal soon, as bulls might have gained significant control over the price to help it find support. The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only f ...

HealthCCSng V2.0 introduces additional 'zero calcium' categorization of coronary artery calcium (CAC) and generates a numerical calcium score with corresponding CAC detection category output Marks second FDA 510(k) clearance of HealthCCSng product PETACH TIKVA, Israel, Aug. 21, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that its deep-learning medical imaging analytics subsidiary, Nanox.AI, received 5 ...

Nano-X Imaging Ltd. (NASDAQ:NNOX) Q2 2024 Earnings Conference Call August 20, 2024 8:30 AM ET Company Participants Mike Cavanaugh - IR Erez Meltzer - CEO Ran Daniel - CFO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Scott Henry - AGP Ross Osborn - Cantor Fitzgerald Operator Good day, and thank you for standing by. Welcome to the Nano-X Second Quarter 2024 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a que ...

Financial Performance - Generated $2.7 million in revenue in Q2 2024, a 3.8% increase from $2.6 million in Q2 2023[2] - Reported a net loss of $13.6 million in Q2 2024, down from a net loss of $17.4 million in Q2 2023, representing a decrease of $3.8 million[5] - Total revenue for the six months ended June 30, 2024, was $5,252 thousand, a 4.4% increase from $5,029 thousand for the same period in 2023[23] - Net loss for the six months ended June 30, 2024, was $(25,816) thousand, compared to $(29,125) thousand for the same period in 2023, reflecting an improvement in net loss[23] - The company reported a basic and diluted loss per share of $(0.45) for the six months ended June 30, 2024, compared to $(0.53) for the same period in 2023[23] - The company reported a basic and diluted loss per share of $0.28 for the six months ended June 30, 2024, compared to $0.37 for the same period in 2023[72] Revenue Breakdown - Revenue from teleradiology services was $2.5 million for both reported and comparable periods, with a gross profit margin of approximately 15%[8] - Revenue from AI solutions was $113 thousand in Q2 2024, with a gross loss of $2.0 million, compared to $53 thousand and a gross loss of $2.1 million in Q2 2023[9] - Total revenues for the six months ended June 30, 2024, were $5,252,000, with the Nanox.ARC division contributing $116,000, Radiology Services $4,926,000, and AI Solutions $210,000[64] - Approximately 96% of the company's total revenue for the six months ended June 30, 2024, was generated in the United States[68] Expenses - Research and development expenses decreased to $4.8 million in Q2 2024 from $6.9 million in Q2 2023, reflecting a decrease of $2.1 million[9] - General and administrative expenses were $5.9 million in Q2 2024, down from $7.6 million in Q2 2023, a decrease of $1.7 million[10] - Total operating expenses for the six months ended June 30, 2024, were $22,725 thousand, a decrease of 14.7% from $26,695 thousand for the same period in 2023[23] - GAAP research and development expenses were $10,032,000, with Non-GAAP adjustments resulting in a net of $8,716,000[76] - GAAP general and administrative expenses reached $10,958,000, with Non-GAAP adjustments bringing it down to $8,662,000[77] Cash and Assets - As of June 30, 2024, the company had total cash and equivalents of $64.2 million, down from $82.8 million as of December 31, 2023, a decrease of $18.6 million[14] - Total current assets decreased to $69,626 thousand as of June 30, 2024, down 21.5% from $88,635 thousand at December 31, 2023[22] - Cash and cash equivalents decreased to $38,982 thousand as of June 30, 2024, down 30.5% from $56,377 thousand at December 31, 2023[22] - As of June 30, 2024, the total cash, cash equivalents, and restricted cash equivalents for Nano-X Imaging Ltd. amounted to $38,982 thousand[30] - The company’s total assets as of June 30, 2024, were $195,721,000, with $114,380,000 from Nanox.ARC, $20,714,000 from Radiology Services, and $60,627,000 from AI Solutions[64] Liabilities and Equity - Total liabilities decreased to $20,586 thousand as of June 30, 2024, down 11.0% from $23,134 thousand at December 31, 2023[22] - Total shareholders' equity as of June 30, 2024, was $175,135 thousand, a decrease of 10.4% from $195,514 thousand at December 31, 2023[22] - The company reported a total of $24,884 million in debt securities due within one year as of June 30, 2024, down from $26,006 million as of December 31, 2023[46] Operational Developments - The company installed Nanox.ARC systems in seven states and has a robust sales pipeline[2] - Nanox.AI received FDA 510K clearance for HealthCCSng V2.0, enhancing its AI cardiac solution capabilities[2] - The company received FDA clearance for its multi-source Nanox.ARC system on April 28, 2023, enhancing its product offerings[31] - The company maintains contingency plans for manufacturing and assembly locations due to the ongoing security situation in Israel, which has not materially impacted operations as of June 30, 2024[33] Legal and Settlement Matters - The company entered into a settlement agreement for $8 million related to class action litigation, with $5 million deposited by the company and $3 million by the D&O insurance carrier[49] - The company has not yet responded to a claim filed in Israel demanding approximately $26.26 million, which includes $1.26 million for unpaid consulting fees and $25 million for claimed securities[50] Shareholder Information - The company had a total of 58,497,123 ordinary shares issued and outstanding as of June 30, 2024, an increase from 57,778,628 shares as of December 31, 2023[55] - The company granted a total of 203,500 options and 190,000 RSUs to employees during the six months ended June 30, 2024, with a fair value of $1,102 thousand for the options granted[57] - The company granted a total of 140,000 RSUs on April 16, 2024, and 50,000 RSUs to the CEO on June 25, 2024, with a fair value of $1,298 and $326, respectively[60] Market and Stock Information - The expected volatility of the company's stock is 80.29%, with a risk-free interest rate of 4.23%[60]

Accelerated the deployment of Nanox ARC in the US market, Submitted a new 510k application to the FDA to expand Nanox.ARC indications to include general use, including chest Nanox.AI Receives FDA 510K Clearance for HealthCCSng V 2.0, upgraded version of its AI Cardiac Solution Management to host conference call and webcast Tuesday, August 20, 2024 at 8:30 AM ET PETAH TIKVA, Israel, Aug. 20, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) ("Nanox" or the "Company"), an innovative medical imaging t ...